tiprankstipranks
Cizzle Biotechnology Enters Strategic North American Partnership
Company Announcements

Cizzle Biotechnology Enters Strategic North American Partnership

Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.

Pick the best stocks and maximize your portfolio:

Cizzle Biotechnology Holdings PLC has entered a strategic licensing and partnership agreement with Cizzle Bio Inc for the North American market, securing a $300,000 upfront royalty payment. This exclusive deal aims to launch Cizzle’s CIZ1B biomarker lung cancer blood test in the USA and Canada, fostering significant revenue streams and equity participation. With support from a highly experienced management team and partnerships with leading cancer centers, the company is poised for a full market launch in 2025.

For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskCizzle Biotech Nears Major US Licensing Deal
TipRanks UK Auto-Generated NewsdeskCizzle Biotech Advances Lung Cancer Detection
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App